2021国际共识推荐:儿童NMDA受体抗体脑炎的治疗  

International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis

作　　者：张童童(翻译) 葛许华(审核)[1] ZHANG Tong-tong;GE Xu-hua(Pediatric Intensive Care Unit,Children’s Hospital of Nanjing Medical University,Nanjing 210008,China)

机构地区：[1]南京医科大学附属儿童医院急诊/重症医学科,南京210008

出　　处：《中国合理用药探索》2022年第3期1-15,共15页Chinese Journal of Rational Drug Use

摘　　要：NMDA受体抗体脑炎(NMDARE)具有特征性的神经和精神病学症状,NMDA受体抗体阳性,目前被认为是儿科最常见的自身免疫性脑炎之一。NMDARE的治疗策略,尤其是对于二线治疗的时机、长期免疫治疗方法等,仍具有较大的差异。来自北美、欧洲、亚洲等国家或地区的27位儿童神经科、风湿科等专业的专家代表,采用2-stepDelphi方法,就儿童NMDARE相关疾病的严重性、治疗方案及声明,以及改善和复发等,达成了关于儿童NMDARE治疗的国际共识。NMDA receptor antibody encephalitis(NMDARE) has characteristic neurological and psychiatric symptoms, and NMDA receptor antibody is positive. At present, it is considered to be one of the most common autoimmune encephalitis in pediatrics. There are still great differences in the treatment strategies for NMDARE, especially in the timing of second-line treatment and long-term immunotherapy. 27 expert representatives from North America, Europe, Asia and other countries/regions, engaged in pediatric neurology,rheumatology and other specialties, adopted the 2-step Delphi method to reach an international consensus on the treatment of NMDARE in children on the severity, treatment plan and statement, improvement and relapse of pediatric NMDARE-related diseases.

关 键 词：NMDA受体抗体脑炎 国际共识 儿童 治疗 利妥昔单抗 

分 类 号：R720.5[医药卫生—儿科]